Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
Melanoma (Skin)

About this trial
This is an interventional treatment trial for Melanoma (Skin) focused on measuring stage IV melanoma, recurrent melanoma
Eligibility Criteria
DISEASE CHARACTERISTICS: Diagnosis of metastatic melanoma Measurable disease Disease progression while receiving prior standard treatment No ocular or mucosal primary site No uncontrolled brain metastases PATIENT CHARACTERISTICS: Age 16 and over Performance status ECOG 0-1 Life expectancy More than 3 months Hematopoietic WBC at least 3,000/mm^3 Platelet count at least 90,000/mm^3 No coagulation disorders Hepatic Bilirubin no greater than 1.6 mg/dL (less than 3.0 mg/dL in patients with Gilbert's syndrome) AST/ALT less than 3 times normal Hepatitis B surface antigen negative Hepatitis C antibody negative Renal Creatinine no greater than 1.6 mg/dL Cardiovascular No major cardiovascular illness Pulmonary No major respiratory illness Immunologic HIV negative No autoimmune disease No active systemic infections No primary or secondary immunodeficiency (e.g., hereditary disorders such as ataxia-telangiectasia or Wiskott-Aldrich syndrome or acquired immunodeficiencies after bone marrow transplantation) No allergy to eggs No prior allergy or untoward reaction to smallpox vaccination (if previously vaccinated) Other Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No close contact with the following individuals for 2 weeks after vaccinia vaccination: Children under 5 years of age Pregnant women Individuals with prior or active eczema or other eczematoid skin disorders Individuals with other acute, chronic, or exfoliative skin conditions (e.g., burns, impetigo, varicella zoster, severe acne, or other open rashes or wounds) Immunosuppressed individuals No active atopic dermatitis No prior or active eczema No active cases of the following conditions: Extensive psoriasis Severe acneiform rash Impetigo Varicella zoster Burns Traumatic or pruritic skin conditions Open wounds No unhealed surgical scars Healed surgical stomas (e.g., colostomy) allowed PRIOR CONCURRENT THERAPY: Biologic therapy No prior recombinant vaccinia or fowlpox vaccines for melanoma No prior vaccination with full length tyrosinase protein, or a vector encoding the full length protein for melanoma Prior individual tyrosinase peptides are allowed No prior high-dose interleukin-2 Chemotherapy Not specified Endocrine therapy No concurrent oral, IV, topical, or inhaled steroids Radiotherapy Not specified Surgery Recovered from prior surgery Other Recovered from prior therapy for melanoma More than 3 weeks since prior systemic therapy for melanoma No other concurrent systemic therapy for melanoma
Sites / Locations
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support